UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement of Cash Flows
Net income	$ 2,722	$ 2,735
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	156	155
Amortization	682	639
(Gain) loss on investments
Provision for (recovery of) losses on accounts receivable	1	0
(Gain)/Loss on disposal of assets		0
Deferred income taxes	(192)	(177)
Stock-based compensation expense	6	7
Changes in operating assets and liabilities:
Accounts receivable	(735)	(958)
Accrued interest and other receivables	19	(171)
Inventories	(518)	(82)
Prepaid expenses and other current assets	(32)	22
Accounts payable	(18)	184
Accrued expenses	(169)	390
Deferred revenue		(25)
Other liability
Total adjustments	(801)	(16)
Net cash provided by operating activities	1,922	2,719
Capital expenditures for property and equipment	(658)	(52)
Capital expenditures for intangible assets
Purchases of investments
Proceeds from sale of investments
Net cash used in investing activities	(658)	(52)
Proceeds from issuance of common stock - options	245	340
Common stock purchased and retired
Payment of taxes for exchange of stock options		(90)
Tax benefit attributable to exercise of stock options	74	175
Repayment of notes payable	(1,012)	(969)
Dividends paid
Net cash (used in) provided by financing activities	(694)	(544)
Effect of exchange rate changes on cash	73	(124)
Net increase in cash and cash equivalents	643	1,999
Cash at beginning of period	14,395	8,871
Cash at end of period	15,038	10,870
Cash paid during the period for income taxes	516	0
Cash paid during the period for interest	$ 88	$ 122